J&J: towards new treatment for prostate cancer
(CercleFinance.com) - The Janssen pharmaceutical companies of Johnson & Johnson today announced the results of a Phase 3 study showing that niraparib + abiraterone acetate + prednisone improved overall survival (OS) and showed a favorable trend in time to cytotoxic chemotherapy (TCC) in patients with metastatic castration-resistant prostate cancer (mCRPC) with BRCA alterations.
The study included 225 BRCA-positive mCRPC patients (the largest population studied to date), where 113 patients were randomized to receive niraparib + PAA (either abiraterone acetate and prednisone) and 112 patients were assigned to placebo + PAA.
The overall survival observed is promising for patients with BRCA-mutated mCRPC, a population more likely to experience poor outcomes, one oncologist said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The study included 225 BRCA-positive mCRPC patients (the largest population studied to date), where 113 patients were randomized to receive niraparib + PAA (either abiraterone acetate and prednisone) and 112 patients were assigned to placebo + PAA.
The overall survival observed is promising for patients with BRCA-mutated mCRPC, a population more likely to experience poor outcomes, one oncologist said.
Copyright (c) 2023 CercleFinance.com. All rights reserved.